GILD
A little trim, a lot of attention
Gilead Sciences is getting the classic Wall Street side-eye after CEO Daniel O’Day sold 10,000 shares at $144.79 each, pocketing about $1.45 million. After the trade, he still held 642,308 shares, so this wasn’t exactly a “run for the exits” moment — more like taking some chips off the table.
Why investors care
Insider sales are messy little clues. They don’t always mean trouble, but when they pile up, people start asking whether management sees a softer road ahead. In Gilead’s case, insiders have sold about 299,280 shares worth roughly $42.82 million over the past 90 days, while insider ownership sits at just 0.30% of the company.
The awkward part
The broader headline here is a bit of a soup sandwich: the article also nods to Gilead beating quarterly estimates with EPS of $1.86, which is the kind of thing that usually makes shareholders breathe a little easier. But the insider-sale chatter is what gives this story its bite, especially if you’re trying to figure out whether the stock’s recent strength has a little too much caffeine in it.
Big picture
If you own GILD, this isn’t an automatic red flag — but it is a reminder that even after a beat, insiders may be choosing cash now over more upside later. That’s the sort of thing that can keep the stock from getting too comfy.